Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
Eugit offers competitive pricing tailored to the needs of various research and medical institutions. Contact us for detailed pricing plans and custom solutions.
Eugit is led by a team of experts in genomics and immunology:
Digital hematology
Match with like-minded professionals for 1:1 conversations
Go from Slack Chaos to Clarity in Minutes
Personalize 1000s of landing pages in under 30 mins
The first LLM for document parsing with accuracy and speed
AI Assistants for SaaS professionals
AI-powered phone call app with live translation
Delightful AI-powered interactive demos—now loginless
AI Motion Graphics Copilot
Pop confetti to get rid of stress & anxiety, 100% AI-free
Smooth payments for SaaS